ANIP vs OGN
ANIP: A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and strategic acquisitions. OGN: A diversified pharmaceutical company spun from Merck focusing on established branded medicines and medical devices for women's health, infectious disease, and other therapeutic areas.
Side-by-side fundamentals
| Metric | ANIP | OGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $77.61 | $13.52 | |
| Market cap as of 2026-07-23 | $1.8B | $3.6B | |
| P/E as of 2026-07-23 | 19.75 | 14.43 | OGN lower |
| PEG as of 2026-07-23 | 1.17 | 2.14 | ANIP lower |
| Net margin as of 2026-07-23 | +10.0% | +4.0% | ANIP higher |
| Gross margin as of 2026-07-23 | +60.8% | +52.8% | ANIP higher |
| Operating margin as of 2026-07-23 | +13.4% | +8.7% | ANIP higher |
| ROE as of 2026-07-23 | +17.8% | +29.9% | OGN higher |
| ROA as of 2026-07-23 | +6.6% | +1.9% | ANIP higher |
| Debt / equity as of 2026-07-23 | 1.09 | 9.49 | ANIP lower |
| Revenue growth (YoY) as of 2026-07-23 | +37.0% | -2.1% | ANIP higher |
| Revenue CAGR (3y) SEC XBRL | +40.8% | +0.2% | ANIP higher |
| Dividend yield as of 2026-07-23 | +0.0% | +0.6% | OGN higher |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 0.47 | 1.52 | |
| 1-year return as of 2026-07-22 close | +21.0% | +37.7% | OGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.